Cozad Asset Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $315K | Buy |
2,007
+40
| +2% | +$6K | 0.02% | 377 |
|
|
2026
Q1 | $300K | Sell |
1,967
-231
| -11% | -$35.4K | 0.02% | 361 |
|
|
2025
Q4 | $303K | Hold |
2,198
| – | – | 0.02% | 352 |
|
|
2025
Q3 | $282K | Buy |
2,198
+40
| +2% | +$4.88K | 0.02% | 366 |
|
|
2025
Q2 | $261K | Hold |
2,158
| – | – | 0.02% | 364 |
|
|
2025
Q1 | $241K | Hold |
2,158
| – | – | 0.02% | 355 |
|
|
2024
Q4 | $210K | Sell |
2,158
-106
| -5% | -$11.3K | 0.02% | 381 |
|
|
2024
Q3 | $260K | Sell |
2,264
-50
| -2% | -$5.67K | 0.02% | 353 |
|
|
2024
Q2 | $246K | Hold |
2,314
| – | – | 0.02% | 348 |
|
|
2024
Q1 | $224K | Sell |
2,314
-104
| -4% | -$10.7K | 0.02% | 365 |
|
|
2023
Q4 | $244K | Hold |
2,418
| – | – | 0.03% | 345 |
|
|
2023
Q3 | $246K | Sell |
2,418
-335
| -12% | -$34K | 0.03% | 324 |
|
|
2023
Q2 | $278K | Hold |
2,753
| – | – | 0.03% | 319 |
|
|
2023
Q1 | $253K | Sell |
2,753
-1,025
| -27% | -$89.5K | 0.03% | 331 |
|
|
2022
Q4 | $343K | Hold |
3,778
| – | – | 0.05% | 279 |
|
|
2022
Q3 | $287K | Buy |
3,778
+280
| +8% | +$23.2K | 0.05% | 283 |
|
|
2022
Q2 | $296K | Hold |
3,498
| – | – | 0.05% | 283 |
|
|
2022
Q1 | $307K | Buy |
3,498
+300
| +9% | +$26K | 0.04% | 288 |
|
|
2021
Q4 | $280K | Sell |
3,198
-165
| -5% | -$13.7K | 0.04% | 291 |
|
|
2021
Q3 | $275K | Hold |
3,363
| – | – | 0.04% | 284 |
|
|
2021
Q2 | $307K | Sell |
3,363
-998
| -23% | -$88.9K | 0.05% | 270 |
|
|
2021
Q1 | $373K | Buy |
4,361
+150
| +4% | +$13.5K | 0.06% | 247 |
|
|
2020
Q4 | $398K | Sell |
4,211
-48
| -1% | -$4.19K | 0.07% | 222 |
|
|
2020
Q3 | $370K | Sell |
4,259
-131
| -3% | -$11.3K | 0.07% | 228 |
|
|
2020
Q2 | $383K | Sell |
4,390
-439
| -9% | -$37.9K | 0.08% | 219 |
|
|
2020
Q1 | $398K | Sell |
4,829
-135
| -3% | -$12K | 0.14% | 144 |
|
|
2019
Q4 | $470K | Sell |
4,964
-383
| -7% | -$34.4K | 0.13% | 150 |
|
|
2019
Q3 | $465K | Hold |
5,347
| – | – | 0.13% | 151 |
|
|
2019
Q2 | $488K | Sell |
5,347
-804
| -13% | -$68K | 0.14% | 145 |
|
|
2019
Q1 | $530K | Hold |
6,151
| – | – | 0.16% | 137 |
|
|
2018
Q4 | $473K | Buy |
6,151
+111
| +2% | +$8.64K | 0.16% | 137 |
|
|
2018
Q3 | $466K | Sell |
6,040
-134
| -2% | -$9.91K | 0.14% | 141 |
|
|
2018
Q2 | $418K | Buy |
+6,174
| New | +$426K | 0.13% | 147 |
|
Other funds holding NVS
Cozad Asset Management's NVS Position: Q2 2026 in Review
Cozad Asset Management increased its Novartis (NVS) stake by 2% in Q2 2026, buying an estimated $6K and bringing the position to 2,007 shares worth $315K. The position accounts for 0.02% of the portfolio, ranked #377.
Cozad Asset Management first reported a position in NVS in Q2 2018 and has held it in 33 quarters since. The position peaked at $530K in Q1 2019. 1,620 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Cozad Asset Management held 2,007 shares of Novartis worth $315K as of Q2 2026.
- Cozad Asset Management bought 40 Novartis shares in Q2 2026, an estimated $6K.
- Novartis made up 0.02% of Cozad Asset Management's portfolio in Q2 2026, its #377 holding.
- Cozad Asset Management first reported a position in Novartis in Q2 2018 and has held it in 33 quarters since.
- Cozad Asset Management's Novartis position peaked at $530K in Q1 2019.
- 1,620 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Cozad Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.